This page contains the latest updates and news from BianchiSchwald, from press releases to publications by our lawyers, to changes in the legal landscape. Want to know more? Please contact us directly.
We are delighted to announce that Mr. Sébastien Maury and Ms. Hélène Weidmann have joined the partnership of our firm. With Sébastien Maury in Zurich and Hélène Weidmann in Lausanne, there are now 16 partners and in total 46 lawyers and legal professionals at 4 locations at your disposal for competent and solution-oriented legal advice.
Corum and BianchiSchwald coorganise two executive seminars on the latest Tech M&A market trends. Focusing on merge trends and valuations from a strategical perspective, our experts – among which Thomas Schmid, Christoph Gasser and Stefan Scherrer in Zurich, Manuel Bianchi della Porta and Thomas Goossens in Geneva – will provide information on how to achieve an optimal outcome and to avoid mistakes in the process.
BianchiSchwald provided Chiesi Farmaceutici S.p.A. ("Chiesi") with Swiss law advice in relation to its in-licencing of Raxone®-- an orphan drug used in the treatment of Leber's hereditary optic neuropathy ("LHON"), a rare hereditary eye disease that leads to severe vision loss –- from Swiss group Santhera Pharmaceuticals Holding AG ("Santhera"). BianchiSchwald’s team comprised of Manuel Bianchi della Porta and Norbert Schenk acted alongside the international law firm Bird&Bird who served as the lead counsel to Chiesi in this transaction.”
Chiesi has in-licensed the rights to Raxone® in LHON and all other ophthalmological indications worldwide except in the US and Canada, where Santhera retains rights. Chiesi also has the option to acquire the Raxone® business following the satisfaction of certain regulatory milestones, including the completion of certain post-authorization measures and the receipt of certain pricing reimbursement approvals. The total consideration for the deal is up to €93 million (approximately CHF 105 million), comprising an upfront cash payment of €44 million (approximately CHF 50 million) together with a number of sales related milestone payments of up to €49 million (approximately CHF 55 million). Closing of the transaction is subject to customary closing conditions including anti-trust approvals.
Within the AGEFI’s monthly Supplément “Indices”, Thierry Amy gives a description of the bill recently issued by the Swiss Federal Council with a view to introducing new rules for adapting Swiss civil laws and financial regulations in the field of Distributed Shares Ledgers (DSL).
The BianchiSchwald SOLA team has demonstrated impressively that we are not only professionally excellent, but also great from a sportive standpoint. It has reached the outstanding 319 place (out of 1000).
The latest 2019 edition of Bilanz’ and Le Temps' supplements dedicated to the best law firms in Switzerland recommend BianchiSchwald in not less than 12 practice areas (General contract law, Labour law (employer side), Compliance, Energy and environmental law, Mergers and acquisitions, Corporate law, Intellectual property rights, Media law, Public procurement law, Private equity and venture capital, Litigation and procedural law, Restructuring and insolvency law), consolidating its reputation among top law firms of the country. This year’s issues also include an interview with our partner Hans-Peter Schwald on strategic concerns regarding the size of law firms.